Canbridge Pharmaceuticals (HKSE:01228) PB Ratio : (As of Jun. 04, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Canbridge Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-06-04), Canbridge Pharmaceuticals's share price is HK$0.34. Canbridge Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was HK$-0.10. Hence, Canbridge Pharmaceuticals's PB Ratio of today is .

The historical rank and industry rank for Canbridge Pharmaceuticals's PB Ratio or its related term are showing as below:

During the past 5 years, Canbridge Pharmaceuticals's highest PB Ratio was 4.57. The lowest was 0.91. And the median was 2.00.

HKSE:01228's PB Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.55
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Canbridge Pharmaceuticals's average Book Value Per Share Growth Rate was -112.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 72.40% per year.

During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Canbridge Pharmaceuticals was 72.40% per year. The lowest was 72.40% per year. And the median was 72.40% per year.

Back to Basics: PB Ratio

Canbridge Pharmaceuticals PB Ratio Historical Data

The historical data trend for Canbridge Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Canbridge Pharmaceuticals PB Ratio Chart

Canbridge Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

PB Ratio

4.57

3.02

Canbridge Pharmaceuticals Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
PB Ratio	Get a 7-Day Free Trial				4.57	2.86	3.02	5.13	-

Competitive Comparison of Canbridge Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, Canbridge Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Canbridge Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Canbridge Pharmaceuticals's PB Ratio falls into.

Canbridge Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Canbridge Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio	=	Share Price	/	Book Value per Share (Q: Dec. 2023)
	=	0.34	/	-0.103
	=

It can also be calculated from the numbers for the whole company:

PB Ratio

Market Cap

(Total Stockholders Equity

Preferred Stock)

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Canbridge Pharmaceuticals (HKSE:01228) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.

Canbridge Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Canbridge Pharmaceuticals (HKSE:01228) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (HKSE:01228) » Definitions » PB Ratio

Comparable Companies

Traded in Other Exchanges

MF1:Germany

Address

Building 21, No. 388 Xinping Street, Unit 18, 6th Floor, Suzhou Industrial Park,, Suzhou, CHN

Website

https://www.canbridgepharma.com

Canbridge Pharmaceuticals Inc is a global biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.

Executives

Xue James Qun	2101 Beneficial owner
Athos Capital Limited	2102 Investment manager
Moskey Matthew Love	2201 Interest of corporation controlled by you
Schulte-hillen Friedrich Bela	2201 Interest of corporation controlled by you
Athos Asia Event Driven Master Fund	2101 Beneficial owner
Ctx Pharma Holdings Limited	2101 Beneficial owner
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Kolchinsky Peter	2305 Beneficiary of a trust
Ra Capital Management, L.p.	2102 Investment manager
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner
Wuxi Apptec Co., Ltd.
Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2101 Beneficial owner

Canbridge Pharmaceuticals (HKSE:01228) Headlines

No Headlines